SCHEMBL30983520

SCHEMBL30983520

CN1CCN(CCOc2ccc(-c3nc4c(OC5(C)CC5)ncnc4n3Cc3ccncc3)c(Cl)c2)CC1

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 6/20 0.42
▸ TLR7 Q9NYK1 3/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CNR1 P21554 3/20 0.37
▸ CNR2 P34972 2/20 0.37
▸ LRRK2 Q5S007 1/20 0.37
▸ DRD2 P14416 3/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ BMP4 P12644 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983822 0.93 DRD2 (0.42) HRH4TLR7KDM4EALDH1A1CNR1
SCHEMBL30983483 0.92 TLR7 (0.40) HRH4TLR7KDM4EALDH1A1CNR1
SCHEMBL30983415 0.91 HRH4 (0.42) HRH4TLR7KDM4EALDH1A1CNR1
SCHEMBL30983428 0.90 KMT2A (0.43) HRH4TLR7KDM4EALDH1A1CNR1
SCHEMBL30983511 0.90 HRH4 (0.41) HRH4TLR7KDM4EALDH1A1CNR1
SCHEMBL30983423 0.89 HRH4 (0.41) HRH4TLR7KDM4EALDH1A1CNR1
SCHEMBL30983816 0.87 HRH4 (0.40) HRH4TLR7KDM4EALDH1A1CNR1
SCHEMBL30983571 0.87 DRD2 (0.41) HRH4KDM4EALDH1A1CNR1CNR2
SCHEMBL30983561 0.87 PDE2A (0.40) HRH4KDM4EALDH1A1CNR1CNR2
SCHEMBL30983478 0.86 DRD2 (0.41) HRH4TLR7KDM4EALDH1A1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB HRH4 4696/4885TLR7 4408/4885KDM4E 2215/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB HRH4 4696/4885TLR7 4408/4885KDM4E 2215/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB HRH4 4696/4885TLR7 4408/4885KDM4E 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback